BROWSE

Cited 0 times in Scipus Cited Count

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)

DC Field Value Language
dc.contributor.authorSim, SH-
dc.contributor.authorKim, JE-
dc.contributor.authorKim, MH-
dc.contributor.authorPark, YH-
dc.contributor.authorKim, JH-
dc.contributor.authorSuh, KJ-
dc.contributor.authorKoh, SJ-
dc.contributor.authorPark, KH-
dc.contributor.authorKang, MJ-
dc.contributor.authorAhn, MS-
dc.contributor.authorLee, KE-
dc.contributor.authorKim, HJ-
dc.contributor.authorAhn, HK-
dc.contributor.authorKim, HJ-
dc.contributor.authorPark, KU-
dc.contributor.authorByun, JH-
dc.contributor.authorPark, JH-
dc.contributor.authorLee, GW-
dc.contributor.authorLee, KS-
dc.contributor.authorSohn, J-
dc.contributor.authorJung, KH-
dc.contributor.authorPark, IH-
dc.date.accessioned2023-02-13T06:23:22Z-
dc.date.available2023-02-13T06:23:22Z-
dc.date.issued2022-
dc.identifier.issn0960-9776-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/24562-
dc.description.abstractWe investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma(R), in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.-
dc.language.isoen-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols-
dc.subject.MESHBiosimilar Pharmaceuticals-
dc.subject.MESHBreast Neoplasms-
dc.subject.MESHDioxolanes-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHPhysicians-
dc.subject.MESHReceptor, ErbB-2-
dc.subject.MESHTrastuzumab-
dc.titlePhase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)-
dc.typeArticle-
dc.identifier.pmid36029565-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429798-
dc.subject.keywordClinical trial-
dc.subject.keywordctDNA-
dc.subject.keywordHER2 positive-
dc.subject.keywordMetastatic breast cancer-
dc.subject.keywordTrastuzumab biosimilar-
dc.contributor.affiliatedAuthorAhn, MS-
dc.type.localJournal Papers-
dc.identifier.doi10.1016/j.breast.2022.08.002-
dc.citation.titleBreast (Edinburgh, Scotland)-
dc.citation.volume65-
dc.citation.date2022-
dc.citation.startPage172-
dc.citation.endPage178-
dc.identifier.bibliographicCitationBreast (Edinburgh, Scotland), 65. : 172-178, 2022-
dc.identifier.eissn1532-3080-
dc.relation.journalidJ009609776-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Files in This Item:
36029565.pdfDownload
Show simple item record

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

  • License
    sherpa_romeo
    sherpa_juliet

OAK

Ajou University Medical Information & Media Center 164 Worldcup-ro Yeongtong-gu Suwon 16499 Korea / TEL : 031-219-5312
Copyright (c) Ajou University Medical Information & Media Center All Rights Reserved.
AJOU Open Repository는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.

Browse

Guide 아주대학교 의학문헌정보센터